NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07325136

RecruitingPhase 1, Phase 2

Sponsor: Bristol-Myers Squibb

Conditions: Relapsed/Refractory Small Cell Lung Cancer

Interventions: BMS-986525, Pumitamig

Countries: United States, China, Italy, Japan, Romania, Spain

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria

* Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
* Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
* In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.

Exclusion Criteria

* Participants must not have any untreated CNS metastases.
* Participants must not have an active, known or suspected autoimmune disease.
* Participants must not have had a prior organ or tissue allograft.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Locations (13)

Detroit, Michigan, United States
Buffalo, New York, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Nashville, Tennessee, United States
Beijing, Beijing Municipality, China
Shanghai Shi, Shanghai Municipality, China
Rozzano, Milano, Italy
Hirakata, Osaka, Japan
Chuo-ku, Tokyo, Japan
Timișoara, Timiș County, Romania
Craiova, Romania
Madrid, Spain